Role of Anticyclic Citrullinated Peptide in the Diagnosis of Early Rheumatoid Factor-Negative Suspected Rheumatoid Arthritis

Panchagnula, Renuka; Rajiv, S R.; Prakash, Jaya; Chandrashekara, S; Suresh, K

doi:10.1097/01.rhu.0000230483.66042.28

Cited by 15 publications

(12 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent clinical trials suggest that anti-CCP is highly accurate in selectively identifying RA patients [39, 89, 90], and to be of particular diagnostic use in patients who are negative for RF [90]. Current research appears to support the hypothesis that RA patients who are positive or negative for anti-CCP antibodies may constitute two subsets of the RA syndrome with different clinical presentations over time [63].…”

Section: Resultsmentioning

confidence: 99%

A Systematic Review of Serum Biomarkers Anti-Cyclic Citrullinated Peptide and Rheumatoid Factor as Tests for Rheumatoid Arthritis

Taylor

Gartemann

Hsieh

et al. 2011

Autoimmune Diseases

116

100

View full text Add to dashboard Cite

This systematic review assesses the current status of anti-cyclic citrullinated peptide (anti-CCP) and rheumatoid factor (RF) tests in the diagnosis and prognosis of rheumatoid arthritis (RA). We reviewed publications on tests and biomarkers for early diagnosis of RA from English-language MEDLINE-indexed journals and non-MEDLINE-indexed sources. 85 publications were identified and reviewed, including 68 studies from MEDLINE and 17 non-MEDLINE sources. Anti-CCP2 assays provide improved sensitivity over anti-CCP assays and RF, but anti-CCP2 and RF assays in combination demonstrate a positive predictive value (PPV) nearing 100%, greater than the PPV of either of the tests alone. The combination also appears to be able to distinguish between patients whose disease course is expected to be more severe and both tests are incorporated in the 2010 ACR Rheumatoid Arthritis Classification Criteria. While the clinical value of anti-CCP tests has been established, differences in cut-off values, sensitivities and specificities exist between first-, second- and third-generation tests and harmonization efforts are under way. Anti-CCP and RF are clinically valuable biomarkers for the diagnosis and prognosis of RA patients. The combination of the two biomarkers in conjunction with other clinical measures is an important tool for the diagnosis and management of RA patients.

show abstract

Section: Resultsmentioning

confidence: 99%

A Systematic Review of Serum Biomarkers Anti-Cyclic Citrullinated Peptide and Rheumatoid Factor as Tests for Rheumatoid Arthritis

Taylor

Gartemann

Hsieh

et al. 2011

Autoimmune Diseases

116

100

View full text Add to dashboard Cite

show abstract

“…We retrieved 65 publications 6-70 , among them 53 full text articles 6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,22,23,26,29,30,32,34,35,36,37,38,39,41,42,43,45,46,47,48,49,50,51,52,53,54,55,59,60,61,62,63,64,65,66,67,68,69,70 and 12 abstracts 21,…”

Section: Resultsmentioning

confidence: 99%

Diagnostic and Prognostic Value of Antibodies and Soluble Biomarkers in Undifferentiated Peripheral Inflammatory Arthritis: A Systematic Review

Schoels¹,

Bombardier²,

Aletaha³

2011

The Journal of Rheumatology Supplement

View full text Add to dashboard Cite

show abstract

“…Gouty arthriti s and non specifi c reacti ve arthriti s were grouped as ''others". All the pati ents with newly diagnosed rheumatoid arthriti s were evaluated by DAS 28 ESR 22,23,24,25,26,27,28 score aft er six weeks of persistent arthriti s 13 and started on methotrexate at loading dose of 15mg/week 28,29 . Those who had long durati on of disease and had DAS 28 >5.1 at presentati on were started on more than two DMARD including hydroxychloroquine 400 mg and sulfasalazine 1gm 30,31 .…”

Section: Methodsmentioning

confidence: 99%

“…All were instructed to visit in between if any drug complicati ons arose or break through pain occurred. Treatment response in rheumatoid arthriti s was defi ned as the improvement in DAS 28 score by > 1.2 from baseline score 23 . The dose of methotrexate was tapered if possible to lowest 7.5-10mg/week if sustained response was seen, aft er six months.…”

Section: Methodsmentioning

confidence: 99%

Prospective evaluation of clinical profile and treatment outcome of patients presenting with polyarthritis diagnosed as rheumatoid arthritis

Neopane

Sharma

Rayamajhi

2012

Med. J. Shree Birendra Hosp.

View full text Add to dashboard Cite

Introducti on: Polyarthriti s is a common presentati on of pati ents att ending medicine outpati ent department. Among various causes Rheumatoid arthriti s is the commonest and a well established case has disti nct characteristi c features. However the early presentati on of this disease has not been clear thus leading to delay in treatment. The objecti ves of this study was to identi fy the various causes of polyarthriti s in our clinical practi ce, discuss the varied clinical presentati on of rheumatoid arthriti s including early Rheumatoid arthriti s and to evaluate the treatment response during one year follow up. Methods: Prospecti ve longitudinal study conducted in a teaching hospital over a two years periodResults: Rheumatoid arthriti s was the commonest cause of polyarthriti s (77.8%) with a period prevalence of 0.7%. Early presentati on included atypical features like asymmetry, unilateral presentati on, manifesti ng within 2 months to 2 years of diagnosis. 43% (n=18) of the pati ents had swelling and tenderness in overused joints 1.5 years prior to full clinical manifestati on. Flitti ng or migratory joint pain not considered to be a feature of rheumatoid arthriti s was also present in 14.3% (n=6) pati ents with mean durati on of 1.5 years prior to full blown presentati on. MCPJ (metacarpophalyngeal joints) and PIP (proximal interphalyngeal joints) were involved in 90%. Treatment response with Methotrexate as a single DMARD was good as compared with DAS 28 ESR score. Conclusions:RA is a common arthriti s with varied clinical presentati on. Recogniti on of early symptoms is needed for early diagnosis and initi ati on of DMARD. Methotrexate as a DMARD is eff ecti ve and should be initi ated early.

show abstract

Role of Anticyclic Citrullinated Peptide in the Diagnosis of Early Rheumatoid Factor-Negative Suspected Rheumatoid Arthritis

Abstract: Anti-CCP is a useful and highly specific but not absolutely specific or sensitive test to detect RA and supplements rheumatoid factor in the presence of a strong clinical suspicion.

Cited by 15 publications

References 8 publications

A Systematic Review of Serum Biomarkers Anti-Cyclic Citrullinated Peptide and Rheumatoid Factor as Tests for Rheumatoid Arthritis

A Systematic Review of Serum Biomarkers Anti-Cyclic Citrullinated Peptide and Rheumatoid Factor as Tests for Rheumatoid Arthritis

Diagnostic and Prognostic Value of Antibodies and Soluble Biomarkers in Undifferentiated Peripheral Inflammatory Arthritis: A Systematic Review

Prospective evaluation of clinical profile and treatment outcome of patients presenting with polyarthritis diagnosed as rheumatoid arthritis

Contact Info

Product

Resources

About